Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | 88G34 | — |
administer a Bexsero vaccine instead of a Menveo; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a 12-year-old female patient who received Men B NVS (Bexsero) (batch number 88G34, expiry date 30-SEP-2027) for prophylaxis. Co-suspect products included Men ACWY-CRM NVS (Menveo) for prophylaxis. On 10-MAR-2025, the patient received the 1st dose of Bexsero. On an unknown date, the patient received Menveo. On 10-MAR-2025, an unknown time after receiving Bexsero and not applicable after receiving Menveo, the patient experienced wrong vaccine administered (Verbatim: administer a Bexsero vaccine instead of a Menveo). The outcome of the wrong vaccine administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 31-MAR-2025 The registered nurse called and mentioned to administer a Bexsero vaccine instead of a Menveo to a patient which led to, wrong vaccine administered. The nurse explained that the Bexsero vaccine was approved for patients between 10 to 25 years old, but as this was an inadvertent administration. The vaccine administration facility was the same as primary reporter.